organization · Reporting owner
ONE EQUITY PARTNERS VII-A, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AdaptHealth Corp.AHCO · Entity 5183 | 10% owner | March 27, 2026 | March 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AdaptHealth Corp.
Report date March 27, 2026 · Filed March 30, 2026 · Amendment
Jointly reported with OEP VII GP, L.L.C., OEP AHCO Investment Holdings, LLC, ONE EQUITY PARTNERS VII, L.P., ONE EQUITY PARTNERS VII-B, L.P., OEP VII Project A Co-Investment Partners, L.P., OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P., OEP VII General Partner, L.P., CASHIN RICHARD M JR
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee | 16,312,698 |
Last balance in matching sequence
After 2026-03-20 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-03-19 · Purchase · Acquired 727 · Balance 15,865,598 F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.94 to $9.95, inclusive. The reporting persons undertake to provide to AdaptHealth Corp., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F3: (Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Row 2 · 2026-03-20 · Purchase · Acquired 447,100 · Balance 16,312,698 F4: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.81 to $9.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F3: (Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.94 to $9.95, inclusive. The reporting persons undertake to provide to AdaptHealth Corp., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").
F3: (Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.
F4: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.81 to $9.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 20, 2026 Filed Mar 30, 2026 23:49 UTC Amendment | AdaptHealth Corp. AHCO · Entity 5183 | PurchaseCommon Stock | 447,100 | $9.91 | $4,431,699.91 |
DisclosureSEC source: 0001193125-26-132703 · ownership.xml · nonDerivative · entry 2 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Disclosed balance after: 16,312,698 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.81 to $9.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F3 · ownership.nature: (Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| March 19, 2026 Filed Mar 30, 2026 23:49 UTC Amendment | AdaptHealth Corp. AHCO · Entity 5183 | PurchaseCommon Stock | 727 | $9.94 | $7,227.62 |
DisclosureSEC source: 0001193125-26-132703 · ownership.xml · nonDerivative · entry 1 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Disclosed balance after: 15,865,598 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.94 to $9.95, inclusive. The reporting persons undertake to provide to AdaptHealth Corp., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F3 · ownership.nature: (Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| March 12, 2026 Filed Mar 30, 2026 23:32 UTC Amendment | AdaptHealth Corp. AHCO · Entity 5183 | PurchaseCommon Stock | 689,336 | $9.73 | $6,707,170.35 |
DisclosureSEC source: 0001193125-26-132663 · ownership.xml · nonDerivative · entry 3 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Disclosed balance after: 15,864,871 F5 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.55 to $9.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F3 · ownership.nature: (Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| March 11, 2026 Filed Mar 30, 2026 23:32 UTC Amendment | AdaptHealth Corp. AHCO · Entity 5183 | PurchaseCommon Stock | 536,827 | $9.73 | $5,222,306.74 |
DisclosureSEC source: 0001193125-26-132663 · ownership.xml · nonDerivative · entry 2 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Disclosed balance after: 15,175,535 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.64 to $9.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F3 · ownership.nature: (Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| March 10, 2026 Filed Mar 30, 2026 23:32 UTC Amendment | AdaptHealth Corp. AHCO · Entity 5183 | PurchaseCommon Stock | 820,528 | $9.73 | $7,982,670.75 |
DisclosureSEC source: 0001193125-26-132663 · ownership.xml · nonDerivative · entry 1 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Disclosed balance after: 14,638,708 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.58 to $9.95, inclusive. The reporting persons undertake to provide to AdaptHealth Corp., a Delaware corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F3 · ownership.nature: (Continued from Footnote 2) The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| September 11, 2020 Filed Sep 11, 2020 23:50 UTC | AdaptHealth Corp. AHCO · Entity 5183 | ConversionSeries A Convertible Preferred Stock · Derivative | 39,706 | Not disclosed Strike: $13.75 | Not disclosed |
DisclosureSEC source: 0000899243-20-024933 · doc4.xml · derivative · entry 2 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Class A Common Stock · 2,887,709 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Such stockholder approval was obtained on August 27, 2020. The Series A Preferred Stock has no expiration date. F3 · kind: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below). F3 · price: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below). F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Such stockholder approval was obtained on August 27, 2020. The Series A Preferred Stock has no expiration date. F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Such stockholder approval was obtained on August 27, 2020. The Series A Preferred Stock has no expiration date. F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Such stockholder approval was obtained on August 27, 2020. The Series A Preferred Stock has no expiration date. F3 · derivative.underlying_shares: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below). F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Such stockholder approval was obtained on August 27, 2020. The Series A Preferred Stock has no expiration date. F3 · balance_after: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below). F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Such stockholder approval was obtained on August 27, 2020. The Series A Preferred Stock has no expiration date. F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F2 · ownership.nature: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| September 11, 2020 Filed Sep 11, 2020 23:50 UTC | AdaptHealth Corp. AHCO · Entity 5183 | ConversionClass A Common Stock | 2,887,709 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-024933 · doc4.xml · nonDerivative · entry 1 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 13,818,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below). F3 · shares: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below). F3 · price: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below). F3 · acquired: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below). F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F2 · balance_after: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. F3 · balance_after: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below). F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F2 · ownership.nature: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 20:18 UTC | AdaptHealth Corp. AHCO · Entity 5183 | OtherSeries A Convertible Preferred Stock · Derivative | 5,454 | Not disclosed Strike: $13.75 | Not disclosed |
DisclosureSEC source: 0000899243-20-023282 · doc4.xml · derivative · entry 4 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 39,706 Underlying: Class A Common Stock · 396,650 shares Expires not disclosed F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · kind: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F3 · shares: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F3 · price: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · derivative.underlying_shares: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F2 · ownership.nature: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 20:18 UTC | AdaptHealth Corp. AHCO · Entity 5183 | OtherSeries A Convertible Preferred Stock · Derivative | 5,454 | Not disclosed Strike: $13.75 | Not disclosed |
DisclosureSEC source: 0000899243-20-023282 · doc4.xml · derivative · entry 3 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 39,706 Underlying: Class A Common Stock · 396,650 shares Expires not disclosed F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · kind: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F3 · shares: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F3 · price: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · derivative.underlying_shares: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F2 · ownership.nature: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 20:18 UTC | AdaptHealth Corp. AHCO · Entity 5183 | OtherClass A Common Stock | 1,501,501 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-023282 · doc4.xml · nonDerivative · entry 2 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 10,930,471 F3 · kind: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F3 · shares: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F3 · price: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F3 · acquired: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F2 · balance_after: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F2 · ownership.nature: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 20:18 UTC | AdaptHealth Corp. AHCO · Entity 5183 | OtherClass A Common Stock | 1,501,501 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-023282 · doc4.xml · nonDerivative · entry 1 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 10,930,471 F3 · kind: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F3 · shares: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F3 · price: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F3 · acquired: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F2 · balance_after: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions. F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). F2 · ownership.nature: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:30 UTC | AdaptHealth Corp. AHCO · Entity 5183 | OtherSeries A Convertible Preferred Stock · Derivative | 3,134 | Not disclosed Strike: $13.75 | Not disclosed |
DisclosureSEC source: 0000899243-20-021871 · doc4.xml · derivative · entry 4 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 39,706 Underlying: Class A Common Stock · 227,927 shares Expires not disclosed F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · derivative.underlying_shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:30 UTC | AdaptHealth Corp. AHCO · Entity 5183 | OtherSeries A Convertible Preferred Stock · Derivative | 3,134 | Not disclosed Strike: $13.75 | Not disclosed |
DisclosureSEC source: 0000899243-20-021871 · doc4.xml · derivative · entry 3 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 39,706 Underlying: Class A Common Stock · 227,927 shares Expires not disclosed F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · derivative.underlying_shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:30 UTC | AdaptHealth Corp. AHCO · Entity 5183 | OtherClass A Common Stock | 862,983 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-021871 · doc4.xml · nonDerivative · entry 2 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 10,930,471 F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · acquired: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. F2 · balance_after: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:30 UTC | AdaptHealth Corp. AHCO · Entity 5183 | OtherClass A Common Stock | 862,983 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-021871 · doc4.xml · nonDerivative · entry 1 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 10,930,471 F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · acquired: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. F2 · balance_after: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 22:26 UTC | AdaptHealth Corp. AHCO · Entity 5183 | OtherSeries A Convertible Preferred Stock · Derivative | 6,269 | Not disclosed Strike: $13.75 | Not disclosed |
DisclosureSEC source: 0000899243-20-018844 · doc4.xml · derivative · entry 4 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 39,706 Underlying: Class A Common Stock · 455,940 shares Expires not disclosed F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · derivative.underlying_shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 22:26 UTC | AdaptHealth Corp. AHCO · Entity 5183 | OtherSeries A Convertible Preferred Stock · Derivative | 6,269 | Not disclosed Strike: $13.75 | Not disclosed |
DisclosureSEC source: 0000899243-20-018844 · doc4.xml · derivative · entry 3 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 39,706 Underlying: Class A Common Stock · 455,940 shares Expires not disclosed F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · derivative.underlying_shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date. F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 22:26 UTC | AdaptHealth Corp. AHCO · Entity 5183 | OtherClass A Common Stock | 1,725,812 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-018844 · doc4.xml · nonDerivative · entry 2 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 10,930,471 F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · acquired: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. F2 · balance_after: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 22:26 UTC | AdaptHealth Corp. AHCO · Entity 5183 | OtherClass A Common Stock | 1,725,812 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-018844 · doc4.xml · nonDerivative · entry 1 OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner CASHIN RICHARD M JR · CIK 0001172898 · 10% owner Han David · CIK 0001817107 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 10,930,471 F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F3 · acquired: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. F2 · balance_after: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction. F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.